Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016

Watchlist Manager
Shanghai MicroPort Endovascular MedTech Group Co Ltd Logo
Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016
Watchlist
Price: 105.26 CNY -3.02% Market Closed
Market Cap: 13B CNY
Have any thoughts about
Shanghai MicroPort Endovascular MedTech Group Co Ltd?
Write Note

Gross Margin
Shanghai MicroPort Endovascular MedTech Group Co Ltd

74.5%
Current
76%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
74.5%
=
Gross Profit
945.1m
/
Revenue
1.3B

Gross Margin Across Competitors

Country CN
Market Cap 13B CNY
Gross Margin
75%
Country JP
Market Cap 7T JPY
Gross Margin
86%
Country CH
Market Cap 37.9B CHF
Gross Margin
55%
Country DK
Market Cap 178.7B DKK
Gross Margin
68%
Country US
Market Cap 16.1B USD
Gross Margin
70%
Country KR
Market Cap 10.3T KRW
Gross Margin
15%
Country CN
Market Cap 49B CNY
Gross Margin
72%
Country US
Market Cap 6.5B USD
Gross Margin
65%
Country CA
Market Cap 6.4B USD
Gross Margin
61%
Country US
Market Cap 5.7B USD
Gross Margin
47%
Country UK
Market Cap 4.6B GBP
Gross Margin
56%
No Stocks Found

Shanghai MicroPort Endovascular MedTech Group Co Ltd
Glance View

Market Cap
13B CNY
Industry
Health Care

Shanghai MicroPort Endovascular MedTech Group Co Ltd stands as a testament to China's burgeoning capabilities in the medtech landscape. The company was born from a vision to develop innovative solutions for treating cardiovascular diseases, which are among the leading causes of mortality worldwide. MicroPort Endovascular crafts specialized medical devices aimed at minimally invasive therapies, particularly in the vascular intervention domain. They produce stents, embolization coils, and vascular grafts—tools essential for intricate procedures like repairing damaged blood vessels or preventing life-threatening aneurysms. By aligning with cutting-edge technological advancements and rigorous clinical testing, MicroPort Endovascular has cemented its reputation as a trusted partner for medical professionals seeking reliable, effective, and technologically advanced instruments. MicroPort Endovascular’s revenue model is intrinsically linked to the global demand for cardiovascular solutions. With increasing incidences of cardiovascular diseases, partly due to lifestyle shifts and an aging population, the firm strategically positions itself in both domestic and international markets to capitalize on this demand. Their business operations span research and development, manufacturing, and distribution, allowing them to maintain control over quality and innovation while optimizing costs. Revenue flows from direct sales to hospitals and healthcare providers, as well as partnerships with distributors, ensuring widespread market penetration. Their continuous investment in R&D not only drives the introduction of new products but also enhances existing ones, thereby maintaining a competitive edge in a field where innovation is tantamount to success.

Intrinsic Value
176.77 CNY
Undervaluation 40%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
74.5%
=
Gross Profit
945.1m
/
Revenue
1.3B
What is the Gross Margin of Shanghai MicroPort Endovascular MedTech Group Co Ltd?

Based on Shanghai MicroPort Endovascular MedTech Group Co Ltd's most recent financial statements, the company has Gross Margin of 74.5%.